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Human cerebrospinal f uid (CSF) has been found to contain several different molecular forms of IGF-specif- 
ic binding proteins (BPS). Qualitatively, they are similar to those present in serum, although their relative 
proportions are very different, as well as to those present in the culture media of brain tissue from which 
these BPS presumably arise. One particular form of BP is predominant in CSF. It has an M, of 34000, as 
estimated by SDS-polyacrylamide gel electrophoresis followed by transfer onto nitrocellulose, and an iso- 
electric point around 5.0 based on chromatofocusing. It has a selective affinity for IGF-II (N 4 x lOlo M-l) 
as shown by competitive binding experiments in which biosynthetic IGF-I was about 40-times less potent 
than native IGF-II in displacing 1Z51-labelled IGF-II. These findings are in agreement with the preponder- 
ance of IGF-II in nervous tissue and in CSF and suggest hat this BP plays an important role in the interac- 
tion of IGF-II with its target cells. 
( CerebrospinalJluid) Insulin-like growth factor Insulin-like growth factor-binding protein 
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1. INTRODUCTION 
In [1,2] we found that insulin-like growth fac- 
tors (IGFs) and their binding proteins (BPS) are 
produced by nervous tissue in culture and that the 
BPS are also present in cerebrospinal fluid (CSF) 
[3]. The biosynthesis of IGFs by nervous tissue has 
since been confirmed and IGF-II has been shown 
to be the predominant form in both nervous tissue 
and CSF [4-71. The aim of this study was to 
characterize the BPS in CSF. The results indicate 
the preponderance of a BP with an M, of 34000 
and a selective affinity for IGF-II, from which an 
important physiological role in the interaction of 
IGF-II with its target cells can be inferred. 
2. MATERIALS AND METHODS 
2.1. Biological samples 
CSF samples were collected during neuroradio- 
logical examination of otherwise healthy subjects 
with herniated intervertebral discs. A pool was 
made up from samples taken from 20 subjects, 
concentrated by ultrafiltration and then stored at 
-25°C. Pools of serum were made from samples 
from healthy subjects and hypopituitary patients. 
Samples of cerebral cortex were obtained from one 
adult (healthy tissue excised during surgery on a 
deep lesion) and two 2dweek-old foetuses (thera- 
peutic abortions) and maintained in organ culture 
as described [l]. CSF and serum samples were 
taken simultaneously from one of the foetuses. 
2.2. Peptides 
IGF-I (Prep. 1:4) and IGF-II (Prep. 9 SE IV) 
purified from human serum were generously pro- 
vided by Dr R.E. Humbel (Zurich). Iodination of 
the IGFs and their subsequent purification were 
performed as in [8]. Biosynthetic IGF-I was kindly 
supplied by Genentech, Inc. (USA). 
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2.3. Analytical gel filtration 
Pooled CSF samples (l-15 ml initial volume) 
were incubated with 12’I-labelled IGF-II (- 12 h, 
4°C) and chromatographed at 4°C on a 1.5 x40 
cm column of Ultrogel AcA 44 (IBF, France) 
equilibrated with 0.02 M Tris-HCl, pH 7.4,0.15 M 
NaCl, 0.05% NaN3, at a flow rate of 10 ml/h (1 
ml/fraction). The column had previously been 
calibrated with different markers (see fig. l), some 
of which (3H-labelled DNA, 14C-labelled oval- 
bumin, 1251) were used as internal markers. 
2.4. Chromatofocusing 
12 ml initial volume of the CSF pool was in- 
cubated with 1251-labelled-IGF-II (- 12 h, 4°C) 
and chromatographed at 4°C on a 0.9 x 60 cm col- 
umn of anion exchanger (PBE 94, Pharmacia, 
Sweden), equilibrated with 0.025 M imidazole-HCl 
buffer, pH 7.4. The proteins were eluted in a gra- 
dient of pH 7.4-4.0 with Polybufffer 74-HCl, pH 
4.0 (12.5% v/v), in 4 ml fractions at a flow rate of 
20 ml/h. 
2.5. SDS-PAGE and Western blotting 
The techniques have been described elsewhere 
[9]. Briefly, the samples, either concentrated or not 
by ultrafiltration, were brought to the same final 
volume (150 ~1) and the same ionic strength (- 0.1 
M NaCl) in the presence of 2.5% SDS, heated for 
2 min at 100°C and subjected to SDS-PAGE (11% 
acrylamide slab gel, 15 x 15 x 0.15 cm) performed 
according to Laemmli [lo], but without reducing 
agent (except in the case of the 14C-labelled ref- 
erence proteins) (Amersham, England). There- 
after, the proteins were electroblotted onto a 
nitrocellulose sheet which was then treated with 
Nonidet P40, BSA and Tween, and finally in- 
cubated with 12sI-labelled IGF-II (200000 cpm/lOO 
cm*) so that the BPS could be detected by auto- 
radiography. 
2.6. Competitive binding studies 
These were performed on BPS prepared from the 
CSF pool which had been gel filtered in acetic acid 
[ 111. Titration curves were first established with 
‘2sI-labelled IGF-I and -II in order to determine 
the concentration of BP yielding 20-25070 binding 
of the tracer. The affinities of the BPS for the IGFs 
were then compared in experiments using 1251- 
labelled IGF-I and -11 (-2000 cpm/tube) and in- 
440 
creasing concentrations of IGF-I and IGF-II. In- 
cubation time was 24 h. Charcoal was used for the 
separation step. 
2.7. BP and IGF assays [8,11] 
These assays all comprised a prior gel filtration 
step in 1 M acetic acid, 0.15 M NaCl, which 
separates the IGFs from their BPS. Binding activity 
measurements were done at six concentrations in 
the presence of 12’I-labelled IGF-II and estimated 
by comparison with a preparation of BPS extracted 
from a pool of normal serum. IGF-I was deter- 
mined by RIA using an anti-Sm-C antiserum 
prepared by Dr J.J. Van Wyk (Chapel Hill, NC) 
and kindly provided by the Hormone Distribution 
Program, NIDKK. IGF-II was measured by 
protein-binding assay using BPS extracted from 
CSF. 
3. RESULTS 
Neutral pH gel filtration of CSF incubated with 
‘251-labelled IGF-II yielded two peaks (fig.l), one 
with a & of 0.74 corresponding to free IGF, the 
other with a Kd of 0.40 corresponding to material 
with an apparent M, of - 40 000. The latter was 
(25, Epm 10-3 
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Fig.1. Gel filtration analysis of CSF IGF-binding pro- 
teins using Ultrogel AcA 44 at pH 7.4. 1 ml CSF was in- 
cubated with ‘251-labelled IGF-II (50000 cpm) with 
(O---O) or without (M) excess IGF (crude prepara- 
tion) and chromatographed in the presence of internal 
markers (see section 2). By way of comparison, the elu- 
tion profiles of the serum IGF-BP complexes are includ- 
ed (0.5 ml normal serum incubated with ‘251-labelled 
IGF-II) (---). 
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displaced by excess IGF and therefore specifically 
bound to the tracer. The presence of BPS and IGFs 
in this material was demonstrated by assays carried 
out after acidic gel filtration (not shown). Neither 
BPS nor IGFs were however detected in the frac- 
tions with &<0.20 which correspond to the elu- 
tion zone of the - 150 kDa IGF-BP complex found 
in the serum (experiment done on a sample con- 
taining 15 ml CSF). 
With chromatofocusing (fig.2), the CSF “‘I- 
labelled IGF-II-BP complexes eluted from the pH 
7.4-4.0 gradient as a single broad peak at pH 
- 5.0. By comparison, the serum -40 kDa IGF- 
BP complex yielded a major peak superimposable 
with that of the CSF BPS and a minor peak at pH 
- 6.0. 
IGF and BP concentrations in CSF were deter- 
mined in 10 subjects (table 1). Total protein con- 
centration in these samples varied from 0.14 to 
0.65 mg/ml (mean, 0.37 mg/ml). The total IGF 
concentration in CSF was 30-times lower than that 
determined for 12 samples of normal adult serum. 
IGF-II concentrations in CSF, however, were 
15-20-times higher than those of IGF-I. Binding 
activity, determined using 1251-labelled IGF-II, was 
approx. one-fifth of that of serum samples. 
In the competitive binding studies (fig.3), the 
CSF BPS exhibited a strong preferential affinity 
for IGF II. With 1251-labelled IGF-II as tracer, the 
“H I:: I I 
Fig.2. Chromatofocusing of CSF IGF-binding proteins. 
The elution profile was obtained after incubation of 12 
ml CSF with ‘**I-labelled IGF-II (M). By way of 
comparison, the elution profile is included of the serum 
-40 kDa IGF-BP complex isolated by gel filtration at 
pH 7.4 (---). 
Table 1 
Levels of IGF-binding proteins and IGFs in the CSF and 
serum of normal adults (means&SE) 
IGF BPS IGF-I IGF-II IGF-II/ 
(mu/ml) (ng/ml) (ngiml) IGF-I 
CSF 
(n= 10) 215+31 2.8+ 0.2 48k 3.8 17 +1.3 
Serum 
(n=12) 967k43 279 *ll 1282k64 4.6 f 0.3 
Samples were assayed after acidic gel filtration. IGF-I 
was measured by RIA and IGF-II by a specific protein- 
binding assay. IGF-BP levels were determined by com- 
paring the binding to ‘251-labelled IGF-II of different 
concentrations of the CSF samples and a reference 
serum BP preparation assigned a value of 1 U IGF-BP 
per ml 
Fig.3. Competitive inhibition of the binding of ‘251- 
labelled IGF-II and ‘251-labelled IGF-I to CSF IGF- 
binding proteins by IGF-II and IGF-I. The quantities of 
BP were those yielding 25% binding of the tracer in the 
absence of cold IGF (Bo). These corresponded to 1 pl 
CSF for ‘*‘I-labelled IGF-II and 20 pl for ‘251-labelled 
IGF-I. Insets: Scatchard plots of the data. 
concentration of IGF-II required for half-maximal 
displacement was about 9-times lower than that of 
native IGF-I. At equal concentrations (determined 
by IGF-I RIA), the biosynthetic IGF-I was about 
5-times less potent than native IGF-I in displacing 
‘251-labelled IGF-II and 40-times less so than IGF- 
II. The specificity of binding was confirmed by the 
absence of cross-reaction with insulin (25 pg/ml). 
The affinity of the CSF BPS for IGF-II, calculated 
441 
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from Scatchard analysis, was 4.2 & 1.4 x 10”’ M-’ 
and the binding capacity, 5.5 t-05x low9 M, i.e. 
CSF but they were far less abundant than the 34 
kDa form. The 30 kDa BP appeared less distinct in 
41 ng IGF-II bound per ml CSF (mean -+: SD of 6 CSF than in h~opituitary serum or certain other 
determinations). 
With r2”I-1abeiled IGF-I as tracer, IGF-II re- 
biological media (amniotic fluid, liver culture 
medium; unpublished). Very similar migration 
mained more potent than IGF-I, but the margin 
was smaller than that with ‘2SI-labelled IGF-II. 
profiles were obtained from 10 different CSF 
samples, each showing the preponderance of the 34 
Scatchard plots of the data curved upwards, sug- kDa form (fig.5). 
gesting independent classes of binding sites. By way of comparison, fig.4 also shows the 
Western blot analysis: in CSF, there was a migration profiles of CSF BPS from a foetus and 
predominant BP which corresponded to the 34 from the culture media of foetal and adult human 
kDa BP of serum (fig.4). The other serum forms nervous tissue. In the case of the CSF and the 
(41.5, 38.5, 30 and 24 kDa) were also present in culture media from foetus no. 1, the 34 kDa and 24 
r 
initi8,l 
volume 
lmil 
69.0 
Fig.4. Western blot analysis of IGF-binding proteins present in CSF and serum and in one adult and two foetal brain 
culture media. The binding proteins were identified after incubation of the nitrocellulose with 1251-labelled IGF-II. 
Binding specificity was demonstrated by incubation with excess IGF of part of the nitrocellulose containing the trans- 
ferred BPS. The positions of the protein markers (run in the presence of fl-mercaptoethanol) are shown on the right. 
The numbers indicate their A&X IO-” as well as those of the BPS (arrows). 
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Fig.5. Western blot analysis of CSF IGF-binding pro- 
teins from 10 different subjects (see section 3 and table 
1). 130,ul CSF was placed in each slot. At this concentra- 
tion, the 30 and 24 kDa forms were barely detectable. 
kDa forms were predominant, whereas in the 
culture media from foetus no.2, the 34, 30 and 24 
kDa forms dominated. In the adult cerebral cor- 
tex, the 38.5, 34 and 24 kDa forms were pre- 
dominant. 
The chromatofocused CSF material was also 
analysed electrophoretically. The 34 kDa form was 
present in all fractions of the peak, whereas the 
41.5, 38.5 and 30 kDa forms appeared in the se- 
cond half of the peak at pH 4.5 (not shown). 
4. DISCUSSION 
It is well known that in biological fluids the IGFs 
are associated with high-affinity binding proteins 
[12-141. Both IGFs and their BPS are present in 
CSF at concentrations considerably lower than 
those in serum. Nevertheless, the relative concen- 
trations of IGFs and BPS as compared with the 
total protein concentration in CSF were high, be- 
ing about lo- and 60-times higher, respectively, 
than those in serum. Moreover, the preponderance 
of IGF-II in CSF is expressed by an IGF-II/IGF-I 
ratio 4-times that in serum. 
Serum IGF-BP complexes elute from neutral pH 
gel filtration as two peaks, one, which appears to 
be under the control of GH, with an apparent MI 
of - 150000 (‘large’ complex) and the other with 
an apparent M, of - 40 000 (‘small’ complex) 
[ 12-141. The CSF IGF-BP complexes eluted as a 
homogeneous peak with an apparent M, similar to 
that of the small complex, but no material was 
found in the zone corresponding to the large com- 
plex. With chromatofocusing, the CSF complexes 
gave a profile which was partially superimposable 
with that of the serum small complex. 
SDS-PAGE analysis of the CSF BPS followed by 
transfer onto nitrocellulose revealed the same 
molecular forms as those found in serum, but in 
very different proportions. The 41.5 and 38.5 kDa 
forms appeared in minute quantities as compared 
with normal serum where they are concentrated in 
the large complex [15]. The 34 kDa form, which is 
minor in normal serum, was predominant in CSF. 
The 30 kDa form was also more abundant in CSF 
than in serum. Interestingly, the 34 and 30 kDa 
forms are increased in hypopituitary serum, which 
shows that they are not dependent on GH. In ner- 
vous tissue culture media, the 34 kDa form was 
abundant, as was the 30 kDa form in one of the 
foetuses. 
In the Western blot technique we adapted to the 
investigation of IGF-binding proteins, it is neces- 
sary that SDS-PAGE be performed in the absence 
of reducing agents which prevent binding between 
labelled IGF and BPS transferred onto nitrocellu- 
lose [9]. In a previous study involving cross-linking 
of the IGF-BP complexes and SDS-PAGE with or 
without reducing agent, we saw only a wide major 
band at 40 kDa and a minor band at 46 kDa [16]. 
We can therefore infer that the 34 kDa form, 
which is the major CSF BP revealed by Western 
blotting, is not a subunit of a higher molecular 
mass binding protein. 
The particular affinity of the CSF BPS for IGF- 
II has been the basis of their use in a specific assay 
for IGF-II [l 11. Although the ability of native 
IGF-I to displace 1251-labelled IGF-II was 9-times 
lower than that of IGF-II, it was 5-times higher 
than that of biosynthetic IGF-I. This suggests 
either the presence of some contaminating IGF-II 
in the IGF-I prepared from human serum, or small 
structural differences between the native and 
biosynthetic forms of IGF-I. The selective affinity 
of the CSF BPS for IGF-II can be attributed essen- 
tially to the 34 kDa form in view of its abundance 
and since experiments done on the material eluting 
at the beginning of the chromatofocusing peak, 
which contains only the 34 kDa form, yield results 
similar to those obtained with native CSF BPS (not 
shown). The other forms of BP analysed in serum 
and in liver culture media also have distinct af- 
finities for IGF-I and IGF-II [15]. 
The fact that brain explants release into the 
443 
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culture medium IGF-binding proteins similar to 
those in CSF, with a large proportion of the 34 
kDa form, strongly suggests that the CSF BPS arise 
from the nervous system. 
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